VFA
EBS icon

Virtus Fund Advisers’s Emergent Biosolutions EBS Stock Holding History

Virtus Fund Advisers’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,493
Closed -$56K – 1370
2014
Q2 		$56K Buy
+2,493
New +$58.1K ﹤0.01% 1780

Other funds holding EBS

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Virtus Fund Advisers's EBS Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Emergent Biosolutions (EBS) in Q3 2014, closing a stake of 2,493 shares — an estimated $56K sold.

Virtus Fund Advisers first reported a position in EBS in Q2 2014 and held it in 1 quarter. The position peaked at $56K in Q2 2014. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Emergent Biosolutions position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 2,493 Emergent Biosolutions shares in Q3 2014, an estimated $56K.
  • Virtus Fund Advisers first reported a position in Emergent Biosolutions in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Emergent Biosolutions position peaked at $56K in Q2 2014.
  • 162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.